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Abstract
Background Elimination of rosiglitazone in humans is via
hepatic metabolism. The existing studies suggest that
CYP2C8 is the major enzyme responsible, with a minor
contribution from CYP2C9; however, other studies suggest
the involvement of additional cytochrome P450 enzymes
and metabolic pathways. Thus a full picture of rosiglita-
zone metabolism is unclear.
Objective This study aimed to improve the current under-
standing of potential drug–drug interactions and implications
for therapy by evaluating the kinetics of rosiglitazone meta-
bolism and examining the impact of specific inhibitors on its
metabolism using the substrate depletion method.
Methods In vitro oxidative metabolism of rosiglitazone in
human liver microsomes obtained from five donors was
determined over a 0.5–500 lM substrate range including
the contribution of CYP2C8, CYP2C9, CYP3A4, CYP2E1,
and CYP2D6.
Results The maximum reaction velocity was
1.64 ± 0.98 nmolmg-1min-1. The CYP2C8 (69 ± 20%),
CYP2C9 (42 ± 10%), CYP3A4 (52 ± 23%), and CEP2E1
(41 ± 13%) inhibitors all significantly inhibited rosiglita-
zone metabolism.
Conclusion The results suggest that other cytochrome
P450 enzymes, including CYP2C9, CYP3A4, and
CEP2E1, in addition to CYP28, also play an important role
in the metabolism of rosiglitazone. This example demon-
strates that understanding the complete metabolism of a
drug is important when evaluating the potential for drug–
drug interactions and will assist to improve the current
therapeutic strategies.
Key Points
In this study, a more comprehensive picture of
rosiglitazone metabolism was demonstrated.
The work presented here will assist in the better
management of rosiglitazone use in regard to
polypharmacy and pharmacogenetics.
1 Introduction
Rosiglitazone belongs to the synthetic thiazolidinedione
class of drugs that improve insulin sensitivity in humans,
and has been used as a potent glucose-lowering medicine in
the treatment of type 2 diabetes [1–3]. Elimination of
rosiglitazone in humans is mainly metabolic [4] via N-
demethylation and para-hydroxylation of the pyridine ring
[4] and has been reported to be the same in rats and dogs as
in humans [5, 6]. All studies to date suggest that phase II
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sulphation and glucuronidation, and that there is no direct
conjugation of rosiglitazone [4].
It has previously been reported that CYP2C8 is the
major enzyme responsible for rosiglitazone metabolism in
humans, with a minor contribution from CYP2C9 [6].
However, all existing studies of rosiglitazone metabolism
have been undertaken using the metabolite formation
method, in which only the formation of N-desmethyl
rosiglitazone and para-hydroxy rosiglitazone were consid-
ered [6]. While formation of these two metabolites has
been consistently reported in all 47 human liver microsome
samples screened by the Baldwin group [6], in vivo studies
have demonstrated that N-desmethyl- and para-hydroxy-
related metabolites of rosiglitazone (including their con-
jugate forms) account for only *60% of rosiglitazone
eliminated in urine and feces [4]. This suggests that *40%
of rosiglitazone is eliminated in the form of metabolites
that are not related to N-demethylation and para-hydroxy-
lation pathways, and that other metabolic pathways and/or
other cytochrome P450 enzymes also make a major con-
tribution to rosiglitazone metabolism [4]. Furthermore, in
an in vivo study, ketoconazole, a potent inhibitor of
CYP3A4 [7], increased the plasma concentration of
rosiglitazone by *47% [8]. Therefore, it appears that a
complete picture of rosiglitazone metabolism is yet to be
established.
The substrate depletion approach to investigating drug
metabolism, unlike the metabolite formation method used
in existing studies, provides the opportunity to investigate
the total cytochrome P450-mediated metabolism of
rosiglitazone without complete knowledge of the metabo-
lites or access to the known metabolites. This approach is
particularly valuable for obtaining a more complete picture
of the kinetics of a substrate’s metabolism, since the sum of
the activity of all of the enzymes and all the metabolic
pathways that contribute to the metabolism of the parent
drug are considered in the evaluation of enzyme kinetics.
Therefore, the aim of this study was to examine the in vitro
metabolism of rosiglitazone and examine the impact of
specific inhibitors on its metabolism in human liver
microsomes using the substrate depletion method.
2 Materials and Methods
2.1 Chemicals and Reagents
Rosiglitazone maleate was purchased from Selleck
Chemicals LLC (TX, USA); acetonitrile was purchased
from Scharlau Chemie S.A. La. Jota (Barcelona, Spain).
Magnesium sulfate was purchased from Sigma (Steinheim,
Germany). Montelukast was purchased from Sapphire
Bioscience (Beaconsfield, NSW, Australia). DL-Isocitric
acid, isocitric dehydrogenase, b-nicotinamide adenine
dinucleotide phosphate sodium salt, furafylline, quinidine,
13-cis retinoic acid, diethyldithiocarbamate, and sul-
faphenazole were purchased from Sigma-Aldrich (Castel
Hill, NSW, Australia). Ketoconazole and troleandomycin
were purchased from BIOTREND Chemikalien GmbH
(Koln, Germany). Human liver microsomes were pur-
chased from Celsis (In Vitro Technologies, Brussels, Bel-
gium). Detailed information on these human liver
microsomes is provided in Table 1.
Milli-Q water was prepared using a Milli-Q Ultrapure
Water System (Millipore, USA).
2.2 Microsomal Incubation
In this study, a substrate depletion method was used. The
protein concentrations and incubation times for rosiglita-
zone metabolism in the microsomes were optimized to
ensure that the metabolism of rosiglitazone at the incuba-
tion times and protein concentrations used in the final
experiment followed first-order kinetics. Rosiglitazone
metabolism in human liver microsomes (Table 1) was
performed in the incubation media using sodium phosphate
buffer (100 mM, pH 7.4), with a final volume of 100 lL
containing: 40 lg microsomal protein in 50 lL of buffer
(equal to 0.4 mg/mL), 25 lL of the NADPH-generating
system (including 7 mM NADP, 1.25 units isocitric acid
dehydrogenase, 18 mM isocitric acid, and 20 mM mag-
nesium chloride) [9], and 25 lL rosiglitazone (at required
concentrations). Incubations were performed at 37 C in a
shaking water bath for 0–25 min, with sampling times of 0,
5, 7.5, 10, 15, 20, and 25 min. The concentration of the
remaining rosiglitazone in the supernatants was measured
using the analytical method described in Sect. 2.4.
The kinetics of rosiglitazone metabolism were studied at
the following rosiglitazone concentrations: 0.5, 2.5, 5, 10,
20, 40, 60, 80, 100, 200, 350, and 500 lM.
2.3 Inhibition Studies with Chemical Inhibitors
The assessment of the impact of specific P450 enzymes
believed to be involved in the bio-transformation of
Table 1 General information of human liver microsomes
Sample Race Gender Age
CYB Caucasian Female 30
JOX Caucasian Female 52
PIM Caucasian Female 58
YAC Caucasian Male 75
ZIL Hispanic Male 38
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rosiglitazone in humans was performed using two different
sets of experiments.
One set of inhibition studies aimed to examine the
impact of inhibition of P450 enzymes believed to be
involved in the bio-transformation of rosiglitazone
(CYP2C8 and CYP2C9) on metabolism kinetics. These
experiments were performed across the full substrate con-
centration range between 0.5 and 500 lM using the same
incubation conditions as described above. In this set of
experiments, 40 lg microsomal protein in 25 lL of buffer
(instead of in 50 lL of buffer) was used, thus allowing the
addition of the inhibitor (25 lL), and the final volume of
the incubation media remained the same at 100 lL. These
inhibition studies were performed using 0.02 lM mon-
telukast (CYP2C8) [10] and 2.5 lM sulfaphenazole
(CYP2C9) [11].
The second set of inhibition studies aimed to screen the
impact of specific P450 enzyme inhibitors other than
CYP2C8 and CYP2C9 in the metabolism of rosiglitazone.
These experiments were performed at a rosiglitazone
concentration of 10 lM in triplicate, with the same incu-
bation conditions as above. These inhibition studies were
performed using 0.02 lM montelukast (CYP2C8), 2.5 and
10 lM sulfaphenazole (CYP2C9), 1 lM ketoconazole
(CYP3A4) [6], 10 lM furafylline (CYP1A2) [6], 1 lM
quinidine (CYP2D6) [6], 142 lM 13-cis retinoic acid
(CYP2C8) [6], 40 lM troleandomycin (CYP3A4) [6], and
40 lM diethyldithiocarbamate (CYP2E1) [12], as well as
both montelukast 0.02 lM (CYP2C8) and sulfaphenazole
2.5 lM (CYP2C9) in combination.
All inhibitions were performed at 37 C in a shaking
water bath for 0–25 min, with sampling times of 0, 5, 7.5,
10, 15, 20, and 25 min. In the inhibition study with fur-
afylline, troleandomycin, and diethyldithiocarbamate, there
was a further 10-min pre-incubation before adding
rosiglitazone and initiation of sampling at the abovemen-
tioned time points [6, 12]. Appropriate controls for the
inhibition studies with the final methanol concentrations
above 0.1% [13] were performed in individual human liver
microsomes.
2.4 Quantification of Rosiglitazone in Incubated
Microsomal Samples
The concentrations of rosiglitazone in incubated samples
were determined using the high-performance liquid chro-
matography (HPLC) assay described in detail previously
[14]. Briefly, the microsomal reaction was stopped by the
addition of 300 lL of ice cold acetonitrile. The samples
were then vortexed briefly before centrifugation at
16,200 rpm (12,2009g) for 20 min at 4 C to separate the
precipitated protein and supernatant. Then 20 lL of this
supernatant was injected onto the HPLC system, and the
concentration of the remaining rosiglitazone in the super-
natants was measured using the HPLC assay. The detection
of peaks was performed by using the fluorescence detector
set at excitation and emission wavelengths 247 and
367 nm, respectively. The range of standard curve cali-
bration was between 0.15 and 10 lM. Dilutions of one in
20 or one in 50 were applied after precipitation for samples
with higher concentrations of rosiglitazone than those
within the calibration curve range. The incubated samples
with substrate concentrations of 20, 40, 60, 80, and 100 lM
were diluted one in 20 with the mobile phase before
injection into the HPLC. Samples with substrate concen-
trations of 200, 350, and 500 lM were diluted one in 50
with mobile phase before injection into the HPLC system.
2.5 Data Analysis and Determination of Enzyme
Kinetics
The depletion rate constant (Kdep) of rosiglitazone meta-
bolism at each substrate concentration was calculated from
the Ln concentration versus time profile, and then the
concentration of rosiglitazone at time zero (C0) was cal-
culated. These were determined from the velocity of
rosiglitazone metabolism in the microsomes over the full
substrate range of 0.5–500 lM. To do this, the concentra-
tion of remaining rosiglitazone at each time point was
transformed logarithmically (Ln concentration) and the
slope (Kdep) and the intercept of the Ln concentration over
time were estimated via linear regression of Ln concen-
tration over time. C0 was then calculated from the intercept
as the exponent of the intercept. Then the initial reaction
velocity at time zero (v) at each substrate concentration
was calculated from Kdep and C0 using Equation (1). The
reaction velocity at each substrate concentration was
expressed as nmolmg-1min-1. Microsoft Excel (2007)
was used for the calculations of Kdep, C0, and v.
Equation 1: Calculating reaction velocity using Kdep and
C0:
v ¼ C0  Kdep
To evaluate the enzyme kinetics of rosiglitazone
metabolism, single enzyme kinetic models (Equations 2,
3, and 4) were fitted to each reaction velocity profile
(velocity/substrate concentration).
Equation 2: Michaelis–Menten kinetics (MM, with two
parameters):
v ¼ Vmax  S
Km þ S
Equation 3: Michaelis–Menten with substrate inhibition
kinetics (MM,IS, with three parameters):
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v ¼ Vmax  S
Km þ Sþ Ki  S2
Equation 4: Allosteric (cooperative) kinetics with three
parameters:
v ¼ Vmax  S
n
Knprim þ Sn
where Vmax is the maximum velocity; Km is the substrate
concentration at which the reaction velocity is 50% of
Vmax; S is substrate concentration; Ki is the constant indi-
cating the degree of substrate inhibition; n is equivalent to
the allosteric coefficient for cooperative substrate binding;
Kprime (K
0) is the substrate concentration at which the
reaction velocity equals 50% of Vmax (equivalent to Km
derived by the MM equation).
All fitting of the models was performed using Prism
software (GraphPad Prism v5.01, GraphPad Software, Inc.
CA, USA). The most appropriate enzyme kinetic model
was selected according to the F test. Where the F test could
not calculate the best fit because of equal parameters
between two tested models, Akaike’s information criterion
(AIC) was used to determine the most appropriate enzyme
kinetic model.
The inhibition data at a rosiglitazone concentration of
10 lM were expressed as the percentage of rosiglitazone
depletion in the presence of the inhibitor compared with the
control (with no inhibition). The mean of rosiglitazone
metabolism in the presence of each inhibitor was compared
with the control using the Student’s t test. The correlation
analyses between the total activity of rosiglitazone meta-
bolism and the activity of individual P450 enzymes (pro-
vided by the manufacturer) were conducted using Pearson
correlation analysis. All statistical analyses were performed
using Prism software (GraphPad Prism v5.01, GraphPad
Software, Inc. CA, USA).
3 Results
3.1 Kinetics of Rosiglitazone Metabolism
Rosiglitazone metabolism was NADPH dependent, and the
enzyme kinetic model of Michaelis–Menten with substrate
inhibition best described the kinetics of rosiglitazone
metabolism in the majority of human liver microsome
samples (Fig. 1). The kinetic parameters obtained from
best model were as follows: Km between 17.1 and 29.8
(25 ± 5.57) lM, Vmax between 0.89 and 3.12
(1.64 ± 0.98) nmolmg-1min-1, and a Ki between 4.25
and 234 (76 ± 91.9) lM. In only one sample (JOX) did the
kinetics of rosiglitazone metabolism not converge in the
MM,IS kinetic model, and it was best described with
allosteric kinetics with a positive cooperativity (allosteric
coefficient of n = 5.87), a K0 of 912 lM, and a Vmax of
0.27 nmolmg-1min-1. The enzyme kinetic parameters of
the metabolism of rosiglitazone in individual human liver
microsomes are presented in Table 2 (see also Fig. 1).
3.2 Impact of Inhibition on Rosiglitazone
Metabolism Kinetics
The inhibition with montelukast or sulfaphenazole resulted
in a slight decrease in the reaction velocity of rosiglitazone
metabolism in all samples across the full substrate con-
centration range (between 0.5 and 500 lM) (Fig. 2). The
kinetic parameters obtained for the best fitted enzyme
kinetic model for the metabolism of rosiglitazone in indi-
vidual human liver microsomes in the presence of the
CYP2C8 or CYP2C9 inhibitors are provided in Table 2. In
the presence of montelukast, a Km between 12.3 and
82.8 (33 ± 33.5) lM, a Vmax between 0.66 and
3.91 (1.72 ± 1.5) nmolmg-1min-1, and a Ki between 9.1
and 859 (311 ± 388) lM were observed. In the presence
of sulfaphenazole, the Km was in the range of 22.2–55.1
(39.1 ± 15) lM, Vmax was in the range of 1.08–5.4
(2.2 ± 1.8) nmolmg-1min-1, and Ki was between 3.8
and 30.2 (15.8 ± 12.4) lM. For sample JOX, in the pres-
ence of montelukast, the contributing enzyme showed a
positive cooperativity (allosteric coefficient of n = 4.36),
with the K0 of 1667 lM and a Vmax of 0.24 nmolmg-1-
min-1. In the presence of sulfaphenazole, the kinetic
parameters obtained from the allosteric kinetic model for
sample JOX was allosteric coefficient of n = 4.31, a Vmax
of 0.19 nmolmg-1min-1, and a K0 of 205 lM (see
Fig. 2).
3.3 Impact of Inhibition on Rosiglitazone
Metabolism at 10 lM
The results of inhibition experiments at a single 10 lM
rosiglitazone concentration are presented in Fig. 3. Among
the inhibitors tested, only quinidine (CYP2D6, 14% inhibi-
tion) and furafylline (CYP1A2, 18% inhibition) did not
significantly (P[ 0.05) decrease rosiglitazone metabolism
compared with the rosiglitazone metabolism with no inhi-
bition. In the presence of montelukast (CYP2C8, 49% inhi-
bition), sulfaphenazole (CYP2C9, 30% inhibition at 2.5 lM
and 42% inhibition at 10 lM), ketoconazole (CYP3A4, 52%
inhibition), troleandomycin (CYP3A4, 41% inhibition),
13-cis retinoic acid (CYP2C8, 69% inhibition), and
diethyldithiocarbamate (CYP2E1, 41% inhibition), and in
the combination of both montelukast and sulfaphenazole
(CYP2C8 and CYP2C9, 71% inhibition), there was a sig-
nificant (P\ 0.05) decrease in rosiglitazone metabolism
compared with the no inhibition condition (see Fig. 3).
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4 Discussion
This study describes for the first time the evaluation of
rosiglitazone metabolism in human liver microsomes using
the substrate depletion method. Previous studies conducted
using the product formation method reported that para-
hydroxylation and N-demethylation are the main pathways
of rosiglitazone metabolism in human liver microsomes,
with the major contribution of CYP2C8 and a minor
contribution of CYP2C9 [6]. In this study, we took a very
different approach (substrate depletion) to Baldwin’s group
(formation of metabolites) to assessing rosiglitazone
metabolism and showed that further to the contribution of
CYP2C8 andCYP2C9, CYP3A4 and CYP2E1 also con-
tribute to the metabolism of rosiglitazone. The enzyme
kinetics reported earlier using the product formation
method for para-hydroxylation or N-demethylation of
rosiglitazone in three human liver microsomes and two
Fig. 1 Rosiglitazone metabolism velocity profile in human liver microsomes (with no inhibition). The solid line represents the curve of the best
fit; the inset is the corresponding Eadie–Hofstee plot. HLM human liver microsomes
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CYP2C8 SupersomesTM demonstrated ordinary Michaelis–
Menten kinetics [6]. However, in the present study, using
the substrate depletion method (which considers the sum of
the activity of all the contributing enzymes), rosiglitazone
metabolism exhibited substrate inhibition kinetics in four
samples and allosteric kinetics in one sample. This indi-
cates that the kinetics of rosiglitazone metabolism in total
(the sum of the total metabolism via all the contributing
enzymes) is different to the kinetics of the para-hydroxy-
lation and N-demethylation pathways alone.
The mean Vmax obtained using the substrate depletion
method in the present study was only 0.59-fold of the mean
value reported by Baldwin et al. [6]. This was unexpected,
since Baldwin and colleagues [6] only measured the for-
mation of para-hydroxylation and N-demethylation
metabolites, accounting for only approximately 60% of
total oxidative metabolism [4], whereas the substrate
depletion method used in the present study represents the
sum of the total oxidative metabolism via all the con-
tributing enzymes. One possibility for this apparent dis-
crepancy is that the differences in the Vmax for
rosiglitazone metabolism in our study and that of Baldwin
and colleagues were due to inter-individual differences in
the capacity to metabolize rosiglitazone. It has been
demonstrated that the pharmacokinetics of rosiglitazone
[clearance (Cl) and terminal half-life (t)] demonstrate
inter-individual differences up to 2.6-fold [4]. Furthermore,
the range of rosiglitazone para-hydroxylation was from 1 to
38 nmolmg-1h-1 and its N-demethylation was from 0.8
to 31 nmolmg-1h-1 at the single substrate concentration
of 10 lM in liver microsomes obtained from 47 individuals
[6], resulting in a combined activity in the order of
2–70 nmolmg-1h-1. The rosiglitazone metabolism in our
study at the same concentration ranged from 11 to
47 nmolmg-1h-1 in the five samples we had access to,
which is within the Baldwin’s results range [6]. This sug-
gests that the lower Vmax in our study may have simply
been due to the microsomes used in our experiments being
derived from individuals with a lower capacity for
rosiglitazone metabolism than the three samples used by
Baldwin for the full kinetic experiments which determined
Vmax.
The contribution of the CYP2C8 enzyme to the meta-
bolism of rosiglitazone in human liver microsomes was
demonstrated in both sets of experiments in our study. In
the presence of montelukast over a substrate range of
0.5–500 lM, the Kdep and therefore the initial velocity of
rosiglitazone metabolism decreased in all individual sam-
ples and there were changes in the kinetic parameters of
rosiglitazone metabolism. The decrease in the initial
velocity of rosiglitazone metabolism at a substrate con-
centration of 10 lM (the same concentration as in Bald-
win’s study [6]) was also observed in all of the samples.
Furthermore, in the other set of inhibition studies at a
Table 2 Parameters of the best fitted models for enzyme kinetics with no inhibition and in the presence of CYP2C8 or CYP2C9 inhibitors
HLM Inhibition Kinetic model Vmax (nmolmg-1 min-1) Km/K0 (lM) Ki (lM) n
CYB No MM,IS 2.18 (0.03–4.32)a 26.0 (0–58.9) 20.4 (0–49.2) –
CYP2C8 MM,IS 3.91 (0–14.7) 82.8 (0–337) 9.06 (0–38.4) –
CYP2C9 MM,IS 1.26 (0–5.13) 22.2 (0–109) 14.6 (0–74.7) –
JOX No Allosteric 0.27 (0.22–0.32) 912 (0–10294) – 5.87 (0–14.1)
CYP2C8 Allosteric 0.24 (0.14–0.30) 1664 (0–18309) – 4.36 (0–10.3)
CYP2C9 Allosteric 0.19 (0.06–0.1) 205 (0–1742) – 4.31 (0–10)
PIM No MM,IS 0.90 (4.34–8.55) 17.1 (7.21–26.9) 234 (0–548) –
CYP2C8 MM,IS 0.67 (0.32–1.01) 12.3 (0.4–24) 859 (0–7903) –
CYP2C9 MM,IS 1.27 (0.4–2.13) 26.7 (2.28–51.1) 30.2 (0–63) –
YAC No MM,IS 0.89 (0.46–1.33) 29.8 (9.82–49.7) 54.6 (3.16–106) –
CYP2C8 MM,IS 0.76 (0.15–1.38) 24.5 (0–52.7) 63.3 (0–170) –
CYP2C9 MM,IS 1.08 (0–2.7) 38.8 (0–118) 26.8 (0–83) –
ZIL No MM,IS 3.12 (1.35–4.89) 27.6 (5.39–49.8) 67.3 (0–140) –
CYP2C8 MM,IS 1.53 (0.73–2.32) 13.4 (1.67–25.1) 313 (0–1174) –
CYP2C9 MM,IS 5.40 (0–15.4) 55.1 (0–165) 3.82 (0–11.7) –
HLM human liver microsomes, Ki the constant indicating the degree of substrate inhibition, Km the substrate concentration at which the reaction
velocity is 50% of Vmax, K
0 (Kprime) the substrate concentration at which the reaction velocity equals 50% of Vmax (equivalent to Km derived by
the MM equation), MM,IS Michaelis–Menten with substrate inhibition kinetics, n equivalent to the Hill-coefficient for cooperative substrate
binding, Vmax the maximum reaction velocity
a The 95% confidence interval of the parameter
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Fig. 2 Rosiglitazone metabolism velocity profile in human liver microsomes with CYP2C8 or CYP2C9 inhibition. The solid line represents the
curve of the best fit. HLM human liver microsomes
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rosiglitazone concentration of 10 lM, the percentage of
rosiglitazone depletion in the presence of montelukast or
13-cis retinoic acid was significantly lower than without
inhibition. These findings are in agreement with previous
studies where the contribution of CYP2C8 in the metabo-
lism of rosiglitazone, using the drugs believed to be mainly
specific for CYP2C8, fluvoxamine [15] and trimethoprim
[16], and the CYP2C8 inducer, rifampin [8, 16], has been
demonstrated. However, our study demonstrated that
CYP2C9, CYP3A4, and CYP2E1 also contribute to the
metabolism of rosiglitazone.
In humans, CYP2C8 is genetically polymorphic and the
CYP2C8*3 genotype confers altered metabolic activity of
the CYP2C8 enzyme. The CYP2C8*3 genotype is associ-
ated with decreased oxidative capacity in vitro for pacli-
taxel [17]. In vivo, the CYP2C8*3 genotype has been
associated with increased metabolism of repaglinide and
pioglitazone and also decreased metabolism of R-ibuprofen
[16, 18, 19]. For rosiglitazone, two clinical studies showed
increased clearance of rosiglitazone in association with
CYP2C8*3 genotype [18, 20]; however, two other studies
have shown no significant association between CYP2C8*3
genotype and the pharmacokinetics of rosiglitazone
[14, 21]. Therefore, this again suggests that CYP2C8 is not
the only enzyme involved in the overall rosiglitazone
metabolism.
The contribution of CYP2C9 to the metabolism of
rosiglitazone was demonstrated in both sets of experiments.
In the presence of sulfaphenazole over a substrate range of
0.5–500 lM, there were changes in the kinetic parameters
of rosiglitazone metabolism. It has been reported that
CYP2C9 has a minor contribution to the para-hydroxyla-
tion (*15%) and N-demethylation (*30%) of rosiglita-
zone in human liver microsomes [6]. However, in our
inhibition studies at a substrate concentration of 10 lM, the
contribution of CYP2C9 in the metabolism of rosiglitazone
was significant at the tested inhibitor concentrations, 30%
inhibition at 2.5 lM and 42% inhibition at 10 lM. These
findings suggest that while CYP2C9 might confer a minor
contribution to para-hydroxylation and N-demethylation of
rosiglitazone, it contributes almost the same as CYP2C8 to
rosiglitazone metabolism overall.
The substrate depletion method does not provide infor-
mation on metabolic pathways of a substrate; however, it
can clearly demonstrate the contribution of CYP enzymes
in the overall metabolism of the substrate. In this study, by
using the substrate depletion method, we further demon-
strated that other CYP enzymes, including CYP3A4 and
CYP2E1, play a significant role in rosiglitazone metabo-
lism. In an in vivo study in humans, ketoconazole increased
the mean area under the plasma concentration–time curve
(AUC) of rosiglitazone by 47% and also increased the peak
plasma concentration of rosiglitazone by 17% [8]; how-
ever, the authors concluded that the observed rosiglitazone
inhibition was due to the inhibition of CYP2C8 or CYP2C9
by ketoconazole, despite the fact that ketoconazole is also a
potent inhibitor of CYP3A4. It has been reported that
ketoconazole (as a selective CYP3A4 inhibitor with the Ki
of 0.02–0.11 lM) can inhibit CYP2C8 activity with the Ki
of 2.5 lM [7]. However, in our inhibition studies, the
ketoconazole concentration was 1 lM (\Ki for CYP2C8
inhibition), and therefore, the observed inhibition appears
to be due to selective CYP3A4, rather than CYP2C8,
inhibition. Importantly, this is the same concentration used
by Baldwin et al. [6] in their work examining the formation
of the N-desmethyl and para-hydroxy metabolites. They
observed a 15% decrease in N-demethylation and about 3%
decrease in para-hydroxylation of rosiglitazone, while we
observed a 52% decrease in total rosiglitazone metabolism.
Furthermore, using another selective inhibitor of CYP3A4,
troleandomycin (40 lM), we demonstrated a 40% inhibi-
tion of rosiglitazone metabolism. The inhibition of
CYP2C8 in the presence of 50 lM troleandomycin, which
is slightly higher (1.2-fold) than that used in our work, has
been reported to be less than 10% [7]. Therefore, these
combined results confirm the significant contribution of
CYP3A4 in rosiglitazone metabolism, despite its relatively
minor role in forming the N-desmethyl and para-hydroxy
metabolites.
Our results also demonstrated a *41% inhibition of
rosiglitazone metabolism in the presence of a selective
inhibitor of CYP2E1, diethyldithiocarbamate.
Fig. 3 Inhibition of rosiglitazone metabolism (10 lM) in human
liver microsomes in the presence of CYP inhibitors. *Significant
difference (P\ 0.05) in comparison with control. 13-cis 13-cis
retinoic acid (CYP2C8) 142 lM, Die diethyldithiocarbamate
(CYP2E1) 40 lM, Fur furafylline (CYP1A2) 10 lM, Ket ketocona-
zole (CYP3A4) 1 lM, Mon montelukast (CYP2C8) 0.02 lM,
Mon ? Sul montelukast (CYP2C8) 0.02 lM in combination with
sulfaphenazole (CYP2C9) 2.5 lM, Qui quinidine (CYP2D6) 1 lM,
Sul sulfaphenazole (CYP2C9) 2.5 lM or 10 lM, Tro troleandomycin
(CYP3A4) 40 lM
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Interestingly, Baldwin et al. in their work demonstrated a
significant correlation between N-demethylation of
rosiglitazone with lauric acid x-1 hydroxylase (CYP2E1)
activity in 47 human liver microsomes [6]. However, they
did not further investigate the contribution of CYP2E1 in
rosiglitazone metabolism. Therefore, this is the first study
that has demonstrated the significant contribution of
CYP2E1 in the metabolism of rosiglitazone in human liver
microsomes.
Since rosiglitazone has negligible renal clearance, it
might be more susceptible to metabolic drug interactions.
Databases for prescribing rosiglitazone, such as the Medi-
cal Information Management System (MIMS), indicate that
CYP2C8 is the only responsible enzyme for rosiglitazone
metabolism. In contrast, this study provides a more com-
prehensive picture of rosiglitazone metabolism and sug-
gests that, in addition to CYP2C8, the contribution of
CYP2C9, CYP3A4, and CYP2E1 to the metabolism of
rosiglitazone is significant. The work presented here
highlights the potential for drug–drug interactions to be
underestimated when the assessment is based only on
product formation metabolism studies, since these studies
may not provide information on important metabolic
pathways/enzymes that contribute to overall drug metabo-
lism. Understanding the complete metabolism information
of rosiglitazone will assist in improving the current thera-
peutic strategies and also in better managing its use in
regard to polypharmacy and pharmacogenetics.
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